Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
| Revenue (TTM) | $2.12M |
| Gross Profit (TTM) | $-79.37M |
| EBITDA | $-103.23M |
| Operating Margin | -6649.00% |
| Return on Equity | -548.00% |
| Return on Assets | -49.90% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.11 |
| Price-to-Book | 5.01 |
| Price-to-Sales (TTM) | 74.49 |
| EV/Revenue | 67.3 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.90% |
| Shares Outstanding | $277.80M |
| Float | $251.01M |
| % Insiders | 5.61% |
| % Institutions | 26.86% |
Volatility is currently contracting
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago.
Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HUMA and any ticker you trade — then tracks every position and per-strategy win rate.
